- \n
- Reports $17.3 million in net sales, $2.9 million in gross profit, and 17% gross margin in the first quarter 2026.<\/i><\/li>\n
- Announces operational changes that are expected to generate more than $3 million in additional gross profit on an annualized basis.<\/i><\/li>\n
- 2026 guidance reflects the Company’s emphasis on growth, improved gross margin, and generating positive cash flow.<\/i>\u00a0\n<\/li>\n<\/ul>\n
WIXOM, Mich.–(BUSINESS WIRE<\/a>)–
\nRockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2026.<\/p>\nThis press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260507118333\/en\/<\/a><\/p>\n
![\"Rockwell](\"https:\/\/mms.businesswire.com\/media\/20260507118333\/en\/2797742\/4\/Rockwell_Medical%27s_Profitability_Trend_%282021-2026%29.jpg\")
<\/p>\nRockwell Medical’s Profitability Trend (2021-2026)<\/p>\n<\/div>\n
\n“Our financial and operational performance in the first quarter 2026 builds on the positive trajectory we have established across our key financial metrics, which we expect to continue throughout the remainder of the year,” said Mark <\/a>Strobeck, Ph.D.<\/a>, Rockwell Medical\u2019s President and CEO. “By streamlining our operations, we are on track to generate meaningful cost savings that we believe will support sustained profitability. Our 2026 guidance is centered around strengthening revenue, expanding gross margin, and generating positive Adjusted EBITDA and cash flow.”<\/p>\n
FIRST QUARTER 2026 FINANCIAL HIGHLIGHTS<\/b><\/p>\n
- \n
- \nNet sales for the three months ended March 31, 2026 were $17.3 million, which represents an 8% decrease over net sales of $18.9 million for the same period in 2025. The decrease in net sales was driven by a reduction in purchase volume by one of the Company’s customers.<\/p>\n<\/li>\n
- \nGross profit for the three months ended March 31, 2026 was $2.9 million, which was in line with gross profit for the same period in 2025.<\/p>\n<\/li>\n
- \nGross margin for the three months ended March 31, 2026 was 17%, representing a slight improvement over gross margin of 16% for the same period in 2025.<\/p>\n<\/li>\n
- \nNet loss for the three months ended March 31, 2026 was $1.6 million, representing a slight increase over a net loss of $1.5 million for the same period in 2025.<\/p>\n<\/li>\n
- \nAdjusted EBITDA for the three months ended March 31, 2026 was ($0.3) million, an improvement over Adjusted EBITDA of ($0.4) million for the same period in 2025.<\/p>\n<\/li>\n
- \nCash and cash equivalents and investments available-for-sale at March 31, 2026 was $23.9 million compared to cash and cash equivalents and investments available-for-sale of $25.0 million at December 31, 2025. The decrease in cash of approximately $1.1 million was driven by seasonal items historically incurred in the first quarter, as well as a $500,000 payment associated with our acquisition of the hemodialysis concentrates business from Evoqua Water Technologies, which occurred in July 2023. The final Evoqua payment was made in April 2026.<\/p>\n<\/li>\n<\/ul>\n
- Announces operational changes that are expected to generate more than $3 million in additional gross profit on an annualized basis.<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260507118333\/en\/2797206\/3\/Rockwell_Medical_-_logo_-_BusinessWire.jpg\"){kind=logo}
<\/td>\n<\/tr>\n![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20260507118333\/en\/2797742\/3\/Rockwell_Medical%27s_Profitability_Trend_%282021-2026%29.jpg\")
<\/td>\n<\/tr>\n